L-Lactic Acid

L-Lactic Acid

SCHEMBL407991

CC(O)C(=O)[O-].CC(O)C(=O)[O-].O.[Fe+2]

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1SLC9A3

The experimentally established mechanism targets of L-Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.47
CA1 P00915 4/20 0.38
CA4 P22748 3/20 0.36
CA2 P00918 1/20 0.36
CYP3A4 P08684 2/20 0.35
TSHR P16473 2/20 0.35
NFKB1 P19838 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
L-Lactic Acid SCHEMBL503900 1.00 TP53 (0.47) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL5013207 1.00 TP53 (0.47) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL1292751 1.00 TP53 (0.47) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL29655228 0.96 TP53 (0.50) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL191421 0.96 TP53 (0.50) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL29508771 0.96 TP53 (0.50) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL25270068 0.93
L-Lactic Acid SCHEMBL407161 0.93 TP53 (0.47) TP53CA1CA4CA2CYP3A4
L-Lactic Acid SCHEMBL8462013 0.93
L-Lactic Acid SCHEMBL14119668 0.93 TP53 (0.47) TP53CA1CA4CA2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016976-A1 METHODS AND COMPOSITIONS TO GRAFT BONE USING IRON EXCIPIENTS Zetagen Therapeutics, Inc. (US) 2024-01-18 US claimed
US-20240000996-A1 METHODS AND COMPOSITIONS TO GRAFT BONE USING IRON EXCIPIENTS Zetagen Therapeutics, Inc. (US) 2024-01-04 US claimed
CN-113913016-B Polyarylethersulfone composition and preparation method and application thereof 金发科技股份有限公司 2023-10-03 CN claimed
EP-4181981-A1 METHODS AND COMPOSITIONS TO GRAFT BONE USING IRON EXCIPIENTS Zetagen Therapeutics, Inc. (US) 2023-05-24 EP claimed
CN-113831535-B Preparation method of polyarylethersulfone resin, obtained polyarylethersulfone resin and application 金发科技股份有限公司 2023-05-16 CN claimed
US-11254779-B1 Reworkable ionomers HRL LABORATORIES, LLC (US) 2022-02-22 US claimed
WO-2022015364-A1 METHODS AND COMPOSITIONS TO GRAFT BONE USING IRON EXCIPIENTS Zetagen Therapeutics, Inc. (US) 2022-01-20 WO claimed
CN-113913016-A Polyarylethersulfone composition and preparation method and application thereof 金发科技股份有限公司 2022-01-11 CN claimed
CN-113831535-A Preparation method of polyarylethersulfone resin, polyarylethersulfone resin obtained by preparation method and application of polyarylethersulfone resin 金发科技股份有限公司 2021-12-24 CN claimed
US-20260092381-A1 BIMETALLIC IRON-VANADIUM OXIDE ELECTROCATALYST FOR OXYGEN EVOLUTION REACTION KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2026-04-02 US disclosed
US-20260047581-A1 BIODERIVED FERROMAGNETIC NICKEL-FERRITE (NiFe2O4) NANOPARTICLES IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2026-02-19 US disclosed
US-20260001777-A1 BIODERIVED FERROMAGNETIC COBALT-FERRITE (CoFe2O4) NANOPARTICLES IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2026-01-01 US disclosed
US-20250352936-A1 3D-TRIPTYCENE-BASED MICROPOROUS POLYMER WITH HYDROXYL GROUPS FOR CARBON DIOXIDE CAPTURE AND METHODS OF PREPARATION THEREOF KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2025-11-20 US disclosed
US-20250352693-A1 COMPOSITIONS USING IRON EXCIPIENTS AND THEIR USES INCLUDING FOR THE TREATMENT OF CANCER Zetagen Therapeutics, Inc. (US) 2025-11-20 US disclosed
US-20080032047-A1 PARTICLES AND INKS AND FILMS USING THEM CITIBANK, N.A. 2008-02-07 US disclosed
WO-2008017062-A1 PARTICLES AND INKS AND FILMS USING THEM FRY'S METALS, INC. (US) 2008-02-07 WO disclosed
EP-1876261-A1 Electroless copper and redox couples Rohm and Haas Electronic Materials, L.L.C. (US) 2008-01-09 EP disclosed
WO-2007036291-A2 IMPROVED CELL CULTURE MEDIUM CELLCA GMBH (DE) 2007-04-05 WO disclosed
EP-1704057-A1 LASER IMAGING Sherwood Technology LTD. (GB) 2006-09-27 EP disclosed
WO-2005068207-A1 LASER IMAGING DATALASE LTD. (GB) 2005-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092381-A1 BIMETALLIC IRON-VANADIUM OXIDE ELECTROCATALYST FOR OXYGEN EVOLUTION REACTION FECH, MFAP1, AP2S1 TP53 1882/4885CA1 1108/4885CA4 1405/4885
US-20260047581-A1 BIODERIVED FERROMAGNETIC NICKEL-FERRITE (NiFe2O4) NANOPARTICLES NIT2, NFE2, AIFM2 TP53 4319/4885CA1 498/4885CA4 97/4885
US-20260001777-A1 BIODERIVED FERROMAGNETIC COBALT-FERRITE (CoFe2O4) NANOPARTICLES CFL1, AIFM2, YAP1 TP53 4635/4885CA1 89/4885CA4 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.